Orbimed Advisors LLC
In its 13F for Q3 2024 (holdings as of September 30, 2024, filed November 14, 2024), Orbimed Advisors LLC reported 109 stock positions worth $5.5 billion. Its top holding was Edgewise Therapeutics (EWTX) at 7.3% of the portfolio, followed by Sinovac Biotech (SVA, 6.2%) and Eli Lilly (LLY, 5.5%). Compared with Q2 2024, it opened 17 new positions, sold out of 16, added to 21 and reduced 29. The biggest buy was a new position in MBX Biosciences (MBX) and the biggest sale Janux Therapeutics (JANX, shares −58%).
- Most Recent 13F
- Q2 2026
- Location
- New York, NY
- CIK
- 0001055951
- Portfolio Value
- $5.5B (Q3 2024)
- SEC Filing
- 0001172661-24-005167 ↗ filed Nov 14, 2024
Holdings Value
Holdings 109 stocks · $5.5B
| EWTX Edgewise Therapeutics Inc. | 7.34% | 15,021,721 | $400.9M | No change |
| SVA Sinovac Biotech Ltd. | 6.22% | 2,718,735 | $340.0M | No change |
| LLY Eli Lilly & Co. | 5.47% | 337,600 | $299.1M | No change |
| BSX Boston Scientific Corp. | 5.02% | 3,273,000 | $274.3M | No change |
| ISRG Intuitive Surgical Inc. | 3.90% | 433,800 | $213.1M | Reduce -12.0% |
| ELVN Enliven Therapeutics Inc. | 3.72% | 7,959,538 | $203.3M | No change |
| BIIB Biogen Inc. | 2.88% | 813,000 | $157.6M | Reduce -9.8% |
| MRK Merck & Co. Inc. | 2.73% | 1,316,000 | $149.4M | No change |
| THC Tenet Healthcare Corp. | 2.38% | 782,000 | $130.0M | Reduce -33.4% |
| SYK Stryker Corp. | 2.28% | 344,400 | $124.4M | Add +28.0% |
| SPRY Ars Pharmaceuticals Inc. | 2.20% | 8,288,510 | $120.2M | Reduce -10.3% |
| SRPT Sarepta Therapeutics Inc. | 2.18% | 954,500 | $119.2M | Add +47.8% |
| ARGX Argenx SE - ADR | 2.03% | 204,500 | $110.9M | Reduce -2.2% |
| UNH Unitedhealth Group Inc. | 1.92% | 179,000 | $104.7M | Add +59.8% |
| QTTB Q32 Bio Inc. | 1.84% | 2,252,987 | $100.5M | No change |
| MBX MBX Biosciences Inc. | 1.81% | 3,812,215 | $99.0M | New |
| IONS Ionis Pharmaceuticals Inc. | 1.70% | 2,324,447 | $93.1M | Reduce -2.0% |
| IRON Disc Medicine Inc. | 1.61% | 1,785,571 | $87.7M | No change |
| NTRA Natera Inc. | 1.60% | 687,500 | $87.3M | No change |
| AMGN Amgen Inc. | 1.49% | 252,300 | $81.3M | Add +87.0% |
| THRD Third Harmonic Bio Inc. | 1.43% | 5,779,071 | $78.3M | No change |
| ITGR Integer Holdings Corp. | 1.37% | 575,000 | $74.8M | Add +64.7% |
| AVBP Arrivent Biopharma Inc. | 1.30% | 3,027,328 | $71.1M | No change |
| VRTX Vertex Pharmaceuticals Inc. | 1.29% | 151,000 | $70.2M | No change |
| ALNY Alnylam Pharmaceuticals Inc. | 1.26% | 250,300 | $68.8M | No change |
| TERN Terns Pharmaceuticals Inc. | 1.15% | 7,562,971 | $63.1M | Reduce -0.7% |
| KROS Keros Therapeutics Inc. | 1.08% | 1,018,734 | $59.2M | Reduce -19.7% |
| JANX Janux Therapeutics Inc. | 1.05% | 1,258,566 | $57.2M | Reduce -57.8% |
| ELV Elevance Health Inc. | 1.01% | 106,200 | $55.2M | Reduce -36.8% |
| CRNX Crinetics Pharmaceuticals Inc. | 0.98% | 1,050,055 | $53.7M | Reduce -18.0% |
| TMO Thermo Fisher Scientific Inc. | 0.96% | 84,400 | $52.2M | Reduce -36.1% |
| XTNT Xtant Medical Holdings Inc. | 0.90% | 73,114,592 | $49.4M | No change |
| RNAM Avidity Biosciences Inc. | 0.88% | 1,044,805 | $48.0M | Add +47.9% |
| REGN Regeneron Pharmaceuticals | 0.87% | 45,200 | $47.5M | Add +98.3% |
| EVH Evolent Health Inc. Class A | 0.86% | 1,665,115 | $47.1M | Reduce -36.1% |
| EXAS Exact Sciences Corp. | 0.85% | 679,816 | $46.3M | Add +1.1% |
| SIBN Si-Bone Inc. | 0.85% | 3,305,801 | $46.2M | Add +2.4% |
| SWTX Springworks Therapeutics Inc. | 0.82% | 1,390,631 | $44.6M | Reduce -18.6% |
| PCVX Vaxcyte Inc. | 0.81% | 387,000 | $44.2M | Reduce -51.4% |
| CMPX Compass Therapeutics Inc. | 0.75% | 22,362,850 | $41.1M | No change |
| CYTK Cytokinetics Inc. | 0.74% | 766,906 | $40.5M | Reduce -5.7% |
| SNDX Syndax Pharmaceuticals Inc. | 0.68% | 1,925,300 | $37.1M | No change |
| CRVS Corvus Pharmaceuticals Inc. | 0.67% | 6,943,654 | $36.7M | No change |
| APLS Apellis Pharmaceuticals Inc. | 0.67% | 1,270,400 | $36.6M | Reduce -2.5% |
| XENE Xenon Pharmaceuticals Inc. | 0.66% | 911,420 | $35.9M | Add +5.7% |
| UHS Universal Health Services-B | 0.65% | 156,000 | $35.7M | New |
| ICLR Icon PLC | 0.65% | 123,900 | $35.6M | Reduce -28.8% |
| NBIX Neurocrine Biosciences Inc. | 0.64% | 302,220 | $34.8M | Reduce -32.6% |
| VERA Vera Therapeutics Inc. | 0.55% | 675,872 | $29.9M | No change |
| BIOA Bioage Labs Inc. | 0.54% | 1,423,470 | $29.6M | New |
| SCPH Scpharmaceuticals Inc. | 0.51% | 6,059,528 | $27.6M | Add +9.0% |
| VIR Vir Biotechnology Inc. | 0.49% | 3,573,000 | $26.8M | Add +54.0% |
| PHAT Phathom Pharmaceuticals Inc. | 0.48% | 1,449,073 | $26.2M | New |
| CGON CG Oncology Inc. | 0.48% | 691,114 | $26.1M | New |
| DYN Dyne Therapeutics Inc. | 0.47% | 708,400 | $25.4M | No change |
| CCCC C4 Therapeutics Inc. | 0.46% | 4,377,900 | $25.0M | Add +189.3% |
| MLYS Mineralys Therapeutics Inc. | 0.44% | 2,002,939 | $24.3M | Reduce -0.9% |
| NPCE Neuropace Inc. | 0.43% | 3,406,335 | $23.7M | No change |
| IMTX Immatics NV | 0.42% | 2,006,381 | $22.9M | No change |
| RYTM Rhythm Pharmaceuticals Inc. | 0.42% | 435,900 | $22.8M | Reduce -38.2% |
| 0 | 0.42% | 12,048,773 | $22.8M | No change |
| PRLD Prelude Therapeutics Inc. | 0.41% | 10,909,256 | $22.6M | No change |
| APGE Apogee Therapeutics Inc. | 0.41% | 379,130 | $22.3M | No change |
| NMRA Neumora Therapeutics Inc. | 0.36% | 1,500,000 | $19.8M | No change |
| SLRN Acelyrin Inc. | 0.36% | 4,001,711 | $19.7M | No change |
| CRBP Corbus Pharmaceuticals Holdi | 0.34% | 912,552 | $18.8M | New |
| TYRA Tyra Biosciences Inc. | 0.33% | 768,638 | $18.1M | No change |
| CGEM Cullinan Therapeutics Inc. | 0.33% | 1,070,055 | $17.9M | Reduce -6.8% |
| LXRX Lexicon Pharmaceuticals Inc. | 0.32% | 11,024,000 | $17.3M | Add +88.6% |
| GPCR Structure Therapeutics Inc. | 0.31% | 383,705 | $16.8M | Add +207.0% |
| ACET Adicet Bio Inc. | 0.30% | 11,447,140 | $16.5M | No change |
| MEDP Medpace Holdings Inc. | 0.27% | 44,900 | $15.0M | New |
| ADCT Adc Therapeutics SA | 0.26% | 4,533,801 | $14.3M | Add +5.0% |
| GILD Gilead Sciences Inc. | 0.23% | 151,700 | $12.7M | New |
| BNTX Biontech SE-ADR | 0.22% | 103,000 | $12.2M | New |
| ACAD Acadia Pharmaceuticals Inc. | 0.22% | 764,600 | $11.8M | New |
| RPTX Repare Therapeutics Inc. | 0.21% | 3,322,488 | $11.4M | No change |
| ABCL Abcellera Biologics Inc. | 0.20% | 4,180,768 | $10.9M | No change |
| PMVP PMV Pharmaceuticals Inc. | 0.18% | 6,475,291 | $9.6M | No change |
| AVTX Avalo Therapeutics Inc. | 0.17% | 967,000 | $9.2M | New |
| VSTM Verastem Inc. | 0.16% | 2,862,448 | $8.6M | Add +87.2% |
| LYEL Lyell Immunopharma Inc. | 0.15% | 6,086,001 | $8.4M | Reduce -5.0% |
| OSCR Oscar Health Inc. Class A | 0.14% | 351,618 | $7.5M | New |
| BCAX Bicara Therapeutics Inc. | 0.13% | 271,910 | $6.9M | New |
| PASG Passage Bio Inc. | 0.13% | 9,822,876 | $6.9M | Reduce -3.0% |
| PEPG Pepgen Inc. | 0.12% | 797,358 | $6.8M | New |
| NKTX Nkarta Inc. | 0.12% | 1,480,600 | $6.7M | Add +85.1% |
| IKENA ONCOLOGY INC | 0.11% | 3,539,358 | $6.1M | No change |
| FOLD Amicus Therapeutics Inc. | 0.11% | 570,300 | $6.1M | No change |
| SRRK Scholar Rock Holding Corp. | 0.11% | 742,300 | $5.9M | Reduce -30.9% |
| FATE Fate Therapeutics Inc. | 0.11% | 1,680,580 | $5.9M | Add +24.0% |
| NSPR Inspiremd Inc. | 0.10% | 2,133,405 | $5.7M | No change |
| LBPH Longboard Pharmaceuticals Inc. | 0.10% | 170,000 | $5.7M | New |
| TELA Tela Bio Inc. | 0.10% | 2,161,185 | $5.5M | Reduce -12.1% |
| XFOR X4 Pharmaceuticals Inc. | 0.09% | 7,133,515 | $4.8M | No change |
| KRYS Krystal Biotech Inc. | 0.08% | 23,500 | $4.3M | Reduce -21.6% |
| ARDT Ardent Health Inc. | 0.07% | 206,000 | $3.8M | New |
| TRAW Traws Pharma Inc. | 0.07% | 605,531 | $3.6M | Add +1348.3% |
| MIST Milestone Pharmaceuticals Inc. | 0.06% | 2,000,000 | $3.0M | No change |
| CMMB Chemomab Therapeutics Ltd. | 0.05% | 1,741,273 | $2.7M | Reduce -22.3% |
Options reported separately and not counted above: EVH calls ($7.3M), MRNA calls ($6.7M), SRPT calls ($6.2M), SOLV calls ($4.8M), RNAM calls ($4.6M), SIBN calls ($3.5M), FLNA puts ($2.8M), GERN calls ($1.8M), CCCC calls ($855K).
Portfolio Sells Q2 2024 → Q3 2024
| JANX Janux Therapeutics Inc. | Reduce -57.8% | 1.05% | −1.44 |
| BIIB Biogen Inc. | Reduce -9.8% | 2.88% | −1.27 |
| VRNA Verona Pharma Ltd. | Sold out | 0.00% | −0.82 |
| ELV Elevance Health Inc. | Reduce -36.8% | 1.01% | −0.80 |
| GERN Geron Corp. | Sold out | 0.00% | −0.75 |
| THC Tenet Healthcare Corp. | Reduce -33.4% | 2.38% | −0.72 |
| DXCM Dexcom Inc. | Sold out | 0.00% | −0.65 |
| NBIX Neurocrine Biosciences Inc. | Reduce -32.6% | 0.64% | −0.59 |
| IONS Ionis Pharmaceuticals Inc. | Reduce -2.0% | 1.70% | −0.54 |
| TMO Thermo Fisher Scientific Inc. | Reduce -36.1% | 0.96% | −0.50 |
| SWTX Springworks Therapeutics Inc. | Reduce -18.6% | 0.82% | −0.46 |
| ISRG Intuitive Surgical Inc. | Reduce -12.0% | 3.90% | −0.46 |
| HRTX Heron Therapeutics Inc. | Sold out | 0.00% | −0.45 |
| ICLR Icon PLC | Reduce -28.8% | 0.65% | −0.43 |
| MORF Morphic Holding Inc. | Sold out | 0.00% | −0.41 |
| PCVX Vaxcyte Inc. | Reduce -51.4% | 0.81% | −0.39 |
| APLS Apellis Pharmaceuticals Inc. | Reduce -2.5% | 0.67% | −0.32 |
| ALXO Alx Oncology Holdings Inc. | Sold out | 0.00% | −0.23 |
| MRUS Merus NV | Sold out | 0.00% | −0.18 |
| CRNX Crinetics Pharmaceuticals Inc. | Reduce -18.0% | 0.98% | −0.16 |
| RYTM Rhythm Pharmaceuticals Inc. | Reduce -38.2% | 0.42% | −0.16 |
| PGNY Progyny Inc. | Sold out | 0.00% | −0.15 |
| CYTK Cytokinetics Inc. | Reduce -5.7% | 0.74% | −0.13 |
| TELA Tela Bio Inc. | Reduce -12.1% | 0.10% | −0.13 |
| EVH Evolent Health Inc. Class A | Reduce -36.1% | 0.86% | −0.13 |
| CATX Perspective Therapeutics Inc. | Sold out | 0.00% | −0.10 |
| CGEM Cullinan Therapeutics Inc. | Reduce -6.8% | 0.33% | −0.07 |
| KROS Keros Therapeutics Inc. | Reduce -19.7% | 1.08% | −0.07 |
| SRRK Scholar Rock Holding Corp. | Reduce -30.9% | 0.11% | −0.07 |
| TGTX TG Therapeutics Inc. | Sold out | 0.00% | −0.05 |
| BMRN Biomarin Pharmaceutical Inc. | Sold out | 0.00% | −0.04 |
| ORIC Oric Pharmaceuticals Inc. | Sold out | 0.00% | −0.04 |
| APLM Apollomics Inc. | Sold out | 0.00% | −0.04 |
| PASG Passage Bio Inc. | Reduce -3.0% | 0.13% | −0.03 |
| KRYS Krystal Biotech Inc. | Reduce -21.6% | 0.08% | −0.03 |
| LYEL Lyell Immunopharma Inc. | Reduce -5.0% | 0.15% | −0.03 |
| MLYS Mineralys Therapeutics Inc. | Reduce -0.9% | 0.44% | −0.03 |
| DVAX Dynavax Technologies Corp. | Sold out | 0.00% | −0.03 |
| IVVD Invivyd Inc. | Reduce -28.8% | 0.03% | −0.02 |
| LAKESHORE BIOPHARMA CO LTD | Sold out | 0.00% | −0.02 |
| OMIC Singular Genomics Systems Inc. | Sold out | 0.00% | −0.00 |
| CMMB Chemomab Therapeutics Ltd. | Reduce -22.3% | 0.05% | +0.01 |
| TERN Terns Pharmaceuticals Inc. | Reduce -0.7% | 1.15% | +0.12 |
| ARGX Argenx SE - ADR | Reduce -2.2% | 2.03% | +0.24 |
| SPRY Ars Pharmaceuticals Inc. | Reduce -10.3% | 2.20% | +0.64 |
Portfolio Buys Q2 2024 → Q3 2024
| MBX MBX Biosciences Inc. | New | 1.81% | +1.81 |
| UNH Unitedhealth Group Inc. | Add +59.8% | 1.92% | +0.78 |
| UHS Universal Health Services-B | New | 0.65% | +0.65 |
| AMGN Amgen Inc. | Add +87.0% | 1.49% | +0.65 |
| ITGR Integer Holdings Corp. | Add +64.7% | 1.37% | +0.56 |
| BIOA Bioage Labs Inc. | New | 0.54% | +0.54 |
| PHAT Phathom Pharmaceuticals Inc. | New | 0.48% | +0.48 |
| CGON CG Oncology Inc. | New | 0.48% | +0.48 |
| SYK Stryker Corp. | Add +28.0% | 2.28% | +0.46 |
| REGN Regeneron Pharmaceuticals | Add +98.3% | 0.87% | +0.39 |
| CRBP Corbus Pharmaceuticals Holdi | New | 0.34% | +0.34 |
| CCCC C4 Therapeutics Inc. | Add +189.3% | 0.46% | +0.32 |
| RNAM Avidity Biosciences Inc. | Add +47.9% | 0.88% | +0.30 |
| EXAS Exact Sciences Corp. | Add +1.1% | 0.85% | +0.28 |
| MEDP Medpace Holdings Inc. | New | 0.27% | +0.27 |
| GILD Gilead Sciences Inc. | New | 0.23% | +0.23 |
| BNTX Biontech SE-ADR | New | 0.22% | +0.22 |
| ACAD Acadia Pharmaceuticals Inc. | New | 0.22% | +0.22 |
| GPCR Structure Therapeutics Inc. | Add +207.0% | 0.31% | +0.21 |
| AVTX Avalo Therapeutics Inc. | New | 0.17% | +0.17 |
| SRPT Sarepta Therapeutics Inc. | Add +47.8% | 2.18% | +0.15 |
| OSCR Oscar Health Inc. Class A | New | 0.14% | +0.14 |
| BCAX Bicara Therapeutics Inc. | New | 0.13% | +0.13 |
| PEPG Pepgen Inc. | New | 0.12% | +0.12 |
| LXRX Lexicon Pharmaceuticals Inc. | Add +88.6% | 0.32% | +0.12 |
| LBPH Longboard Pharmaceuticals Inc. | New | 0.10% | +0.10 |
| VIR Vir Biotechnology Inc. | Add +54.0% | 0.49% | +0.08 |
| ARDT Ardent Health Inc. | New | 0.07% | +0.07 |
| VSTM Verastem Inc. | Add +87.2% | 0.16% | +0.07 |
| TRAW Traws Pharma Inc. | Add +1348.3% | 0.07% | +0.06 |
| TIL Instil Bio Inc. | New | 0.04% | +0.04 |
| NKTX Nkarta Inc. | Add +85.1% | 0.12% | +0.03 |
| SCPH Scpharmaceuticals Inc. | Add +9.0% | 0.51% | +0.02 |
| FATE Fate Therapeutics Inc. | Add +24.0% | 0.11% | +0.02 |
| SIBN Si-Bone Inc. | Add +2.4% | 0.85% | +0.02 |
| ADCT Adc Therapeutics SA | Add +5.0% | 0.26% | −0.01 |
| XENE Xenon Pharmaceuticals Inc. | Add +5.7% | 0.66% | −0.01 |
| BIOMX INC | Add +29.8% | 0.03% | −0.06 |
Options Activity Q2 2024 → Q3 2024
| EVH Evolent Health Inc. Class A | call | New | 258,400 | $7.3M |
| PFE Pfizer Inc. | call | Sold out | 250,000 | $7.0Mbefore exit |
| MRNA Moderna Inc. | call | New | 100,000 | $6.7M |
| SOLV Solventum Corp. | call | Reduce -65.3% | 69,300 | $4.8M |
| RNAM Avidity Biosciences Inc. | call | New | 100,000 | $4.6M |
| MRUS Merus NV | call | Sold out | 50,000 | $3.0Mbefore exit |
| FLNA Filana Therapeutics Inc. | put | New | 95,000 | $2.8M |
| GERN Geron Corp. | call | Reduce -33.3% | 400,000 | $1.8M |
| CCCC C4 Therapeutics Inc. | call | New | 150,000 | $855K |
Calls and puts are listed by the shares they cover; their value is not part of the stock holdings above.
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 117 | $5.3B | EWTX, ELVN, LLY, MBX, SVA |
| Q1 2026 | 105 | $4.4B | EWTX, ELVN, LLY, SVA, BSX |
| Q4 2025 | 104 | $4.9B | EWTX, LLY, BSX, SVA, EW |
| Q3 2025 | 98 | $4.2B | EWTX, BSX, LLY, SVA, ELVN |
| Q2 2025 | 97 | $4.0B | SVA, BSX, LLY, EWTX, ELVN |
| Q1 2025 | 106 | $4.2B | SVA, EWTX, BSX, LLY, ELVN |
| Q4 2024 | 111 | $4.8B | EWTX, SVA, BSX, LLY, ISRG |
| Q3 2024 | 109 | $5.5B | EWTX, SVA, LLY, BSX, ISRG |
| Q2 2024 | 108 | $5.0B | SVA, LLY, EWTX, BSX, ISRG |
| Q1 2024 | 112 | $5.4B | SVA, LLY, EWTX, BSX, ISRG |